Matthias Staufenbiel und Basel - Info zur Person

(1 - 6 von 10

)

US Patent for Composition comprising VLP and amyloid beta peptide...

patents.justia.com

Inventors: Ana Graf (Riehen), Matthias Staufenbiel (Lörrach), Thomas Blaettler (Böckten), Paolo Paganetti (Basel) Primary Examiner: Jeffrey ...

Peripheral Aβ Seeds CAA and Parenchymal Amyloidosis | ALZFORUM

www.alzforum.org

In fact, the researchers first found evidence for this two years ago, but waited to publish until, with the help of Matthias Staufenbiel at Novartis in Basel, Switzerland, they reproduced the results in a different laboratory in a different country. First author Yvonne Eisele and colleagues took brain extract from old ...

Alle Infos zum Namen "Matthias Staufenbiel"

GMS | 57th Annual Meeting of the German Society for Neuropathology...

www.egms.de

Matthias Staufenbiel - Novartis Institutes for Biochemical Research, Basel, Switzerland Dietmar Rudolf Thal - Laboratory of Neuropathology ...

Frontiers | Development of Cerebral Microbleeds in the...

www.frontiersin.org

Heterozygote B6, D2-TgN[Thy-APPSWE]-23-tg mice (APP23-tg) provided by Matthias Staufenbiel (Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland) were backcrossed twice with C57BL/6 mice (Janvier, Saint Berthevin Cedex, France) and kept under a h light/dark cycle with ...

Transgenic Mouse Models of Alzheimer's Disease - [PDF Document]

vdocuments.site

260 Transgenic Mouse Models of Alzheimers Disease KLAUS D. BORNEMANN AND MATTHIAS STAUFENBIELa Novartis Pharma, Inc., Nervous System Research, CH Basel,...